· Published by Health Canada · Official notice
This is duplicated text of a letter from CSL Behring Canada, Inc.
Contact the company for a copy of any references, attachments or enclosures.
June 1, 2012
Subject: Association of hemolysis following the use of Privigen® [Immune Globulin Intravenous (Human)], and related labeling update
CSL Behring Canada, Inc. (CSLB), in collaboration with Health Canada, would like to inform you of the risk of hemolysis (damaged or destroyed red blood cells) and hemolytic anemia (where you have less red blood cells because many of them have been either damaged or destroyed) associated with the use of Privigen®. Risk factors for hemolysis associated with Privigen® and similar products (collectively called Intravenous Immune Globulins or IVIgs) have been identified, and are presented below:
IVIgs such as Privigen® are used to treat adults and children:
Reports of hemolysis are extremely rare in patients needing antibody replacement since they are treated with low doses.
Contact your doctor if you experience symptoms of hemolysis as described above or any other signs or symptoms that concern you.
Hospital professionals have also been informed of the risk of hemolysis following Privigen® use.
Managing marketed health product-related adverse reactions depends on health-care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of hemolysis or other serious or unexpected adverse reactions in patients receiving Privigen® should be reported to CSL Behring or to Health Canada.
Please report any adverse events you encounter with CSL Behring Product to CSL Behring U.S. Clinical Safety and Pharmacovigilance: 1-866-915-6958. Please provide the lot number(s) of products associated with reported adverse events whenever possible.
CSL Behring Canada, Inc.
55 Metcalfe Street, Suite 1460
Ottawa, Ontario
K1P 6L5
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Susanne Picard, B. Pharm., M. Sc.
Director, Regulatory Affairs Canada
CSL Behring Canada, Inc.